Lorus Announces a Cooperative Research and Development Agreement with National Cancer Institute
News May 25, 2009
Lorus Therapeutics Inc. has announced extension of a cooperative research program with the U.S. National Cancer Institute (NCI), National Institutes of Health (NIH), which includes its Ribonucleotide Reductase (RNR) targeted RNA-targeted drugs.
Under a Materials Cooperative Research and Development Agreement (MCRADA), the Laboratory of Cancer Biology & Genetics (LCBG) of the NCI will use Lorus' LOR-2501 and LOR-2040, and LOR-1284, in combination with commercially-available drugs, to develop a drug cocktail(s) that is more effective for the treatment of Renal Cell Carcinoma tumors than for normal regenerating kidney. Of specific interest in this regard is the potential usage of this anti-tumor treatment approach in targeting the tumor and not the normal regenerating tissue.
The title of the MCRADA is "Renal Cell Carcinoma as Wounds that do not heal: Drug Combinational Therapy using Lorus Therapeutics' Antisense Oligonucleotides to Ribonucleotide Reductase M1 Polypeptide (RRM1) & RRM2, and siRNA to RRM2". The studies are being conducted at the NCI by Dr. Joseph Riss and the NIH Principal Investigator Dr. Glenn Merlino.
All three drugs that are being evaluated in this cooperative research program have emerged from Lorus' oncology drug discovery program and have been extensively tested in many preclinical models. LOR-1284 is currently in preclinical development as the Lorus' lead siRNA drug targeting RRM2. LOR-2501 and LOR-2040, the Lorus' lead antisense drugs targeting RRM1 and RRM2 respectively, are each in clinical development stage with the primary focus at present on the LOR-2040 Phase II program in Acute Myeloid Leukemia, among several cancer indications studied.
"This MCRADA is an example of the ongoing collaborative research that Lorus strives to undertake in parallel with each of its developmental programs", said Dr. Aiping Young, Lorus' President and CEO. "Such partnership accelerates the knowledge generated by research activities into practical applications and provides a basis for future development opportunities over and above our core development program".
Can Epigenetics Help Explain the Mechanisms of Autism?News
New findings suggest that epigenetic analysis of DNA regions that control gene expression may hold clues to the genetic basis of autism spectrum disorder.READ MORE